📰 What This Document Is 📖

This document is an Annual Report on Form 10-K, which is one of the most comprehensive reports a public company files with the SEC. Think of it as a massive, deep dive into the company's entire year—its finances, its risks, its management's plans, and its history.

Because Absci Corp is in the early, high-risk stages of drug development, the 10-K is crucial for understanding how they plan to make money, what scientific hurdles they face, and the significant financial risks involved. 👉 In short, it tells you the full story, but it is heavily weighted toward scientific detail and future speculation.

🏢 What Absci Corp Does 🧬

In simple terms, Absci is a biopharmaceutical company that uses advanced Artificial Intelligence (AI) to reinvent how drugs are discovered. Instead of using slow, expensive, traditional lab methods, they use their proprietary platform to design potential drugs computationally.

They focus on creating specialized antibodies (therapeutic antibodies) that target "underexplored mechanisms"—meaning areas of biology that haven't been thoroughly studied yet and where there is a high unmet medical need. The entire process is designed to be faster and more capital-efficient than standard drug discovery.

🔬 The AI Drug Creation Platform 🧠

Absci’s entire value proposition is built on its proprietary "Integrated Drug Creation platform." This isn't just software; it’s a sophisticated feedback loop called lab-in-a-loop that connects three elements: AI, wet lab validation, and continuous data analysis.

• AI to Create: Their generative AI models, including the flagship Origin-1 model, can design new antibody structures and sequences ("de novo"). The major breakthrough of Origin-1 is that it targets "zero-prior" epitopes, which are binding sites that scientists have never documented before. This capability significantly expands the potential targets for new drugs.
• Lab-in-a-loop: This is the core mechanism. They use their lab facilities (77,000+ square feet) to test the AI designs in the real world (e.g., using high-throughput Surface Plasmon Resonance). This real-world data is then fed back to the AI models, refining them and making them better for the next cycle.
• Why it matters: This closed-loop system is what allows them to claim capital-efficient development, having advanced their first two internal programs to Investigational New Drug (IND) status in about two years with a total investment of approximately $15 million per program, which is far faster and cheaper than the industry average of 4–6 years and over $50 million.

📜 Business Model and Strategy 🚀

Absci’s revenue generation strategy is structured around three main goals, all leveraging the AI platform:

1. Internal Pipeline: Building and advancing their own portfolio of internally developed drugs. They intend to advance a limited number of these programs, like ABS-201, through clinical development and potential commercialization.
2. Partnerships: Seeking strategic third-party partnerships to develop drugs. This involves up-front fees, research fees, and potential future royalties.
3. Out-licensing: Selling off or licensing other internally generated programs once they reach certain value milestones (from preclinical through early clinical stages).

👉 Their overarching strategy is to maintain their technological differentiation by continuously investing in their team and platform, ensuring they remain the best engine for creating novel, best-in-class therapeutics.

🧪 Lead Candidate: ABS-201 for Androgenetic Alopecia (AGA) 🧑‍🦲

The first major program, ABS-201, is an anti-prolactin receptor (PRLR) antibody. This therapy is being developed for two indications, the first being Androgenetic Alopecia (AGA), commonly known as pattern hair loss.

• The Problem (AGA): AGA is a progressive, multifactorial condition affecting approximately 80 million people in the U.S. Current FDA-approved treatments are limited in efficacy, inconvenient, and do not provide durable growth.
• The Mechanism: ABS-201 targets the PRLR (prolactin receptor) signaling. By inhibiting this signal, the therapy is intended to influence the hair cycle, promoting the anagen (growth) phase and inhibiting the catagen (regression) phase.
• Preclinical Evidence: Studies using human ex vivo hair follicle organ cultures showed that ABS-201 could prolong the anagen phase, increase key hair growth factors (like IGF1 and FGF7), and stimulate keratin production. Furthermore, in a preclinical mouse study, ABS-201 significantly increased hair regrowth compared to the standard drug minoxidil.
• Clinical Plan: A Phase 1/2a clinical trial (HEADLINE™, NCT07317544) began in December 2025 to assess safety and tolerability. They successfully dosed the first three Single Ascending Dose (SAD) cohorts and anticipate reporting interim proof-of-concept data in the second half of 2026, with full proof-of-concept data expected in early 2027.

🩸 Lead Candidate: ABS-201 for Endometriosis 🚺

The same core drug, ABS-201, is also being developed for Endometriosis, a chronic, inflammatory disease that affects up to 10% of women of reproductive age worldwide.

• The Problem: The condition is currently lacking any FDA-approved disease-modifying therapy. The average time to diagnosis remains highly variable, with diagnosis being limited in many settings.
• The Mechanism: Like AGA, the therapy targets PRLR. The signaling pathway is believed to be involved in both endometrial lesion development and chronic pain-related pathways. Because PRLR signaling is independent of sex-hormone pathways, this could offer a non-hormonal treatment option.
• Clinical Plan: The Phase 2 clinical trial for endometriosis is planned for the fourth quarter of 2026, dependent on the data from the ongoing HEADLINE trial.
• Preclinical Evidence: In an endometriosis mouse model, ABS-201 was shown to decrease overall pain experience and was associated with reductions in inflammatory cytokines (like TNFα, IL-1β, and CCL2) in peritoneal fluid.

📉 Strategic Pivot for ABS-101 🔄

Initially, ABS-101 was being developed for Inflammatory Bowel Disease (IBD). However, in May 2025, the company made a strategic decision to prioritize ABS-201 for AGA and endometriosis because those areas presented greater unmet medical needs and potential return.

Due to this pivot, the company plans to seek a partner for ABS-101 rather than advancing it themselves. This partner relationship aims to explore a first-in-class indication outside of IBD.

💡 Preclinical & Future Programs 🌱

While ABS-201 is the current focus, the pipeline is diverse. The company is advancing several early-stage programs, including:

• ABS-301: A potential first-in-class oncology asset, derived using their specialized reverse immunology platform.
• ABS-501: A potentially differentiated HER2 program.

👉 These programs are designed to keep the pipeline robust and provide multiple avenues for future partnerships and development.

🚨 Major Risks and Competitive Landscape ⚠️

The 10-K dedicates significant space to detailing the risks, which are typical for an early-stage biotech firm. The primary concerns center on:

• Clinical Uncertainty: The success of biologic drug development is inherently uncertain. Positive early results are not predictive of later clinical outcomes.
• Capital Needs: The company anticipates incurring significant losses and will need to raise additional capital to fund development. Failure to raise funds on acceptable terms could halt programs.
• Competition: The fields are highly competitive. For example, AGA has established competitors like oral minoxidil, while Endometriosis has other emerging non-hormonal antibody candidates. The platform space itself has competitors (e.g., Generate Biomedicines, Inc.).
• Regulatory Hurdles: Regulatory processes (FDA) are extensive and complex. Failure to comply with any regulation, or delays from the FDA, can severely delay or halt the entire program.

🔐 Intellectual Property and Regulatory Compliance 🛡️

Absci takes its intellectual property (IP) rights extremely seriously because its entire business depends on its proprietary technology.

• Patent Status: As of December 31, 2025, the company holds 69 issued or granted patents and 53 pending patent applications worldwide. These patents cover key aspects of their AI platform, drug design, and internally developed programs.
• Data Protection: Beyond patents, they rely heavily on trade secrets, proprietary assays, and confidentiality agreements to protect their AI algorithms and unique protocols.
• Regulatory Complexity: The filing details the rigorous multi-phase pathway required by the FDA for a drug to be approved, including:
  • Phase 1: Safety and dosage in healthy volunteers.
  • Phase 2: Preliminary efficacy and optimal dosing in a limited patient population.
  • Phase 3: Establishing overall risk/benefit ratio in a large, diverse patient population.

📞 Important Resources and Next Steps 📅

• Corporate Website: Investors and the public should monitor www.absci.com and their investor relations site.
• Key Milestones:
  • First Half of 2026: Expect interim safety and tolerability data from the HEADLINE™ trial.
  • Second Half of 2026: Anticipate additional interim analyses, including evaluation of exploratory efficacy endpoints.
  • Fourth Quarter of 2026: Planned initiation of the Phase 2 clinical trial for ABS-201 in Endometriosis.
  • Early 2027: Anticipated full proof-of-concept data for ABS-201.

🧠 The Analogy

Think of Absci's drug discovery process like building a highly advanced, specialized car. Traditional drug discovery is like drawing the car by hand on graph paper—it takes years, expensive physical testing is needed at every corner, and mistakes are hard to fix. Absci’s AI-driven platform, however, is like having a self-driving factory: the AI blueprints the perfect design (the antibody), the lab validates the materials instantly (the wet lab), and the system continuously learns from every test run to make the next design even better, dramatically speeding up the entire development process.

🧩 Final Takeaway

Absci is a pioneering, high-risk play betting that AI can drastically lower the cost and time of drug discovery. Its success hinges entirely on the continued validation of its flagship drug, ABS-201, and its ability to translate complex AI models into a safe, effective, and approvable biologic therapy.